| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8785632 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar, 2025
(1 year, 5 months from now) | |
| US7230098 | PF PRISM CV | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug, 2025
(1 year, 11 months from now) | |
| US7858643 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Oct, 2029
(6 years from now) | |
| US8217057 | PF PRISM CV | Polymorphs of a c-MET/HGFR inhibitor |
Nov, 2029
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7825137 | PF PRISM CV | Method of treating abnormal cell growth |
May, 2027
(3 years from now) | |
Xalkori is owned by Pf Prism Cv.
Xalkori contains Crizotinib.
Xalkori has a total of 5 drug patents out of which 0 drug patents have expired.
Xalkori was authorised for market use on 26 August, 2011.
Xalkori is available in capsule;oral dosage forms.
Xalkori can be used as treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
The generics of Xalkori are possible to be released after 06 November, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jul 14, 2029 |
| New Indication (I) | Jul 14, 2025 |
Drugs and Companies using CRIZOTINIB ingredient
Market Authorisation Date: 26 August, 2011
Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; ...
Dosage: CAPSULE;ORAL
XALKORI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic